Valsynthese in Grignards collaboration
Swiss fine chemical manufacturer Valsynthese has entered into a manufacturing services agreement, under which it will host Grignard reagents production units based on the proprietary MgFlow Technology of Belgium’s Chemium and offer integrated services based on it. Chemium will commercialise ready-to-use Grignards through its Swiss subsidiary.
MgFlow is described as a “groundbreaking continuous flow process designed especially for the safe manufacturing of Grignard reagents”, featuring temperature control, reduced volumes and new ways of mixing that eliminate the reaction runaway risks that have limited Grignard reagent synthesis. Online QC tools and comprehensive automation can also be integrated into the process.
RELATED ARTICLES
Swiss CDMO Siegfried has inaugurated its new global R&D centre for drug substances at its site in Evionnaz.
Peptides CDMO AmbioPharm, has broken ground on a 650 m2, $28 million expansion project at its Shanghai manufacturing site. This is due to be complete in 2H 2025 and will produce over 8 tonnes/year of crude peptide.
Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.
Biosynth, which supplies critical raw materials and services for diagnostics, vaccines and pharmaceuticals, has officially opened its Biosynth Biological Technology site at Lifebay, a technology park in Suzhou, China.
At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitional year in 2023.
At CPHI in Milan in October, eight Indian CDMOs announced that they have formed a trade group to raise the profile of India’s drug services sector and make it a destination of choice.
